Barclays’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-5,352
| Closed | -$17K | – | 5395 |
|
|
2022
Q2 | $17K | Hold |
5,352
| – | – | ﹤0.01% | 4475 |
|
|
2022
Q1 | $23K | Sell |
5,352
-12
| -0.2% | -$52 | ﹤0.01% | 4416 |
|
|
2021
Q4 | $25K | Sell |
5,364
-2,340
| -30% | -$9.75K | ﹤0.01% | 3932 |
|
|
2021
Q3 | $30K | Sell |
7,704
-6,863
| -47% | -$27.2K | ﹤0.01% | 4271 |
|
|
2021
Q2 | $62K | Sell |
14,567
-516
| -3% | -$2.21K | ﹤0.01% | 4039 |
|
|
2021
Q1 | $64K | Buy |
15,083
+9,251
| +159% | +$51K | ﹤0.01% | 4152 |
|
|
2020
Q4 | $23K | Sell |
5,832
-2,563
| -31% | -$11K | ﹤0.01% | 4652 |
|
|
2020
Q3 | $34K | Sell |
8,395
-2,236
| -21% | -$9.26K | ﹤0.01% | 4763 |
|
|
2020
Q2 | $45K | Buy |
10,631
+3,635
| +52% | +$22.1K | ﹤0.01% | 4984 |
|
|
2020
Q1 | $29K | Sell |
6,996
-14,824
| -68% | -$93.6K | ﹤0.01% | 5516 |
|
|
2019
Q4 | $85K | Buy |
21,820
+6,073
| +39% | +$35.9K | ﹤0.01% | 5554 |
|
|
2019
Q3 | $139K | Buy |
15,747
+1,585
| +11% | +$15K | ﹤0.01% | 5227 |
|
|
2019
Q2 | $132K | Buy |
14,162
+8,029
| +131% | +$60.5K | ﹤0.01% | 5472 |
|
|
2019
Q1 | $39K | Sell |
6,133
-34,776
| -85% | -$227K | ﹤0.01% | 6055 |
|
|
2018
Q4 | $386K | Sell |
40,909
-100,899
| -71% | -$1.52M | ﹤0.01% | 4047 |
|
|
2018
Q3 | $2.85M | Buy |
141,808
+138,889
| +4,758% | +$3.63M | ﹤0.01% | 2469 |
|
|
2018
Q2 | $86K | Sell |
2,919
-708
| -20% | -$21.9K | ﹤0.01% | 5343 |
|
|
2018
Q1 | $108K | Buy |
3,627
+855
| +31% | +$27.6K | ﹤0.01% | 5333 |
|
|
2017
Q4 | $89K | Sell |
2,772
-7,221
| -72% | -$236K | ﹤0.01% | 5338 |
|
|
2017
Q3 | $348K | Sell |
9,993
-3,477
| -26% | -$112K | ﹤0.01% | 3948 |
|
|
2017
Q2 | $401K | Buy |
13,470
+11,200
| +493% | +$321K | ﹤0.01% | 3733 |
|
|
2017
Q1 | $68K | Buy |
2,270
+2,065
| +1,007% | +$52.7K | ﹤0.01% | 5159 |
|
|
2016
Q4 | $4K | Sell |
205
-138
| -40% | -$2.65K | ﹤0.01% | 6238 |
|
|
2016
Q3 | $8K | Buy |
343
+285
| +491% | +$5.37K | ﹤0.01% | 5897 |
|
|
2016
Q2 | $1K | Hold |
58
| – | – | ﹤0.01% | 6285 |
|
|
2016
Q1 | $1K | Sell |
58
-98
| -63% | -$1.75K | ﹤0.01% | 6104 |
|
|
2015
Q4 | $4K | Sell |
156
-9,654
| -98% | -$263K | ﹤0.01% | 5657 |
|
|
2015
Q3 | $265K | Buy |
9,810
+9,589
| +4,339% | +$302K | ﹤0.01% | 3922 |
|
|
2015
Q2 | $5K | Buy |
+221
| New | +$4.55K | ﹤0.01% | 6531 |
|
|
2014
Q3 | – | Sell |
-3,600
| Closed | -$32K | – | 8122 |
|
|
2014
Q2 | $32K | Buy |
+3,600
| New | +$32.9K | ﹤0.01% | 6257 |
|
Barclays's LJPC Position: Q3 2022 in Review
Barclays sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 5,352 shares — an estimated $17K sold.
Barclays first reported a position in LJPC in Q2 2014 and held it in 30 quarters. The position peaked at $2.85M in Q3 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Barclays reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Barclays sold 5,352 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $17K.
- Barclays first reported a position in La Jolla Pharmaceutical Company in Q2 2014 and held it in 30 quarters.
- Barclays's La Jolla Pharmaceutical Company position peaked at $2.85M in Q3 2018.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.